Personalized Monitoring of Response to Anti‐Amyloid Therapy in a Real‐World Cohort using Clinical Assessment and Plasma Biomarkers

Abstract

Background: Blood‐based biomarkers may be a cost‐effective, accessible method for monitoring response to anti‐amyloid therapy (AAT). While plasma biomarkers of Alzheimer’s disease pathology correlate with amyloid and tau measures on PET and change with AAT in clinical trials, data from real‐world cohorts receiving AAT is limited.

The paper